Upadhaya S, Neftelinov ST, Hodge J, Campbell J (2022) Challenges and opportunities in the PD1/PDL1 inhibitor clinical trial landscape. Nat Rev Drug Discov 21(7):482–483. https://doi.org/10.1038/d41573-022-00030-4

Article  CAS  PubMed  Google Scholar 

Wang Y, Zhang H, Liu C, Wang Z, Wu W, Zhang N, Zhang L, Hu J, Luo P, Zhang J, Liu Z, Peng Y, Liu Z, Tang L, Cheng Q (2022) Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts. J Hematol Oncol 15(1):111. https://doi.org/10.1186/s13045-022-01325-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Benson AB, D’Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, Chahal P, Chang DT, Cloyd J, Covey AM, Glazer ES, Goyal L, Hawkins WG, Iyer R, Jacob R, Kelley RK, Kim R, Levine M, Palta M, Park JO, Raman S, Reddy S, Sahai V, Schefter T, Singh G, Stein S, Vauthey JN, Venook AP, Yopp A, McMillian NR, Hochstetler C, Darlow SD (2021) Hepatobiliary cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 19(5):541–565. https://doi.org/10.6004/jnccn.2021.0022

Article  PubMed  Google Scholar 

Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, Goff L, Gupta S, Guy J, Harris WP, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Knox JJ, Kortmansky J, Leaf A, Remak WM, Shroff RT, Sohal DPS, Taddei TH, Venepalli NK, Wilson A, Zhu AX, Rose MG (2020) Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol 38(36):4317–4345. https://doi.org/10.1200/jco.20.02672

Article  CAS  PubMed  Google Scholar 

Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543. https://doi.org/10.1200/jco.2015.61.6870

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15(23):7412–7420. https://doi.org/10.1158/1078-0432.ccr-09-1624

Article  CAS  PubMed  Google Scholar 

Zhao F (2016) Surrogate end points and their validation in oncology clinical trials. J Clin Oncol 34(13):1436–1437. https://doi.org/10.1200/jco.2016.66.4581

Article  PubMed  Google Scholar 

Lee D-W, Jang M-J, Lee K-H, Cho EJ, Lee J-H, Yu SJ, Kim YJ, Yoon J-H, Kim T-Y, Han S-W, Oh D-Y, Im S-A, Kim T-Y (2016) TTP as a surrogate endpoint in advanced hepatocellular carcinoma treated with molecular targeted therapy: meta-analysis of randomised controlled trials. Br J Cancer 115(10):1201–1205. https://doi.org/10.1038/bjc.2016.322

Article  CAS  PubMed  PubMed Central  Google Scholar 

Llovet JM, Montal R, Villanueva A (2019) Randomized trials and endpoints in advanced HCC: role of PFS as a surrogate of survival. J Hepatol 70(6):1262–1277. https://doi.org/10.1016/j.jhep.2019.01.028

Article  PubMed  Google Scholar 

Terashima T, Yamashita T, Toyama T, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S (2019) Surrogacy of time to progression for overall survival in advanced hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis of randomized controlled trials. Liver Cancer 8(2):130–139. https://doi.org/10.1159/000489505

Article  PubMed  Google Scholar 

Prentice RL (1989) Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8(4):431–440. https://doi.org/10.1002/sim.4780080407

Article  CAS  PubMed  Google Scholar 

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, Roberts LR, Zhu AX, Murad MH, Marrero JA (2018) AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 67(1):358–380. https://doi.org/10.1002/hep.29086

Article  PubMed  Google Scholar 

Conforti F, Pala L, Sala I, Oriecuia C, De Pas T, Specchia C, Graffeo R, Pagan E, Queirolo P, Pennacchioli E, Colleoni M, Viale G, Bagnardi V, Gelber RD (2021) Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ 375:e066381. https://doi.org/10.1136/bmj-2021-066381

Article  PubMed  PubMed Central  Google Scholar 

Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL (2020) Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol 38(3):193–202. https://doi.org/10.1200/jco.19.01307

Article  CAS  PubMed  Google Scholar 

Qin S, Chen Z, Fang W, Ren Z, Xu R, Ryoo BY, Meng Z, Bai Y, Chen X, Liu X, Xiao J, Ho GF, Mao Y, Wang X, Ying J, Li J, Zhong W, Zhou Y, Siegel AB, Hao C (2023) Pembrolizumab versus placebo as second-line therapy in patients from asia with advanced hepatocellular carcinoma: a randomized, double-blind, phase III trial. J Clin Oncol 41(7):1434–1443. https://doi.org/10.1200/jco.22.00620

Article  CAS  PubMed  Google Scholar 

Qin S, Kudo M, Meyer T, Finn RS, Vogel A, Bai Y, Guo Y, Meng Z, Zhang T, Satoh T, Hiraoka A, Marino D, Assenat E, Wyrwicz L, Campos MC, Hsing-Tao K, Boisserie F, Li S, Chen Y, Zhu AX (2022) LBA36 Final analysis of RATIONALE-301: Randomized, phase III study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Ann Oncol 33:S1402–S1403. https://doi.org/10.1016/j.annonc.2022.08.033

Article  Google Scholar 

Yau T, Park JW, Finn RS, Cheng AL, Mathurin P, Edeline J, Kudo M, Harding JJ, Merle P, Rosmorduc O, Wyrwicz L, Schott E, Choo SP, Kelley RK, Sieghart W, Assenat E, Zaucha R, Furuse J, Abou-Alfa GK, El-Khoueiry AB, Melero I, Begic D, Chen G, Neely J, Wisniewski T, Tschaika M, Sangro B (2022) Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 23(1):77–90. https://doi.org/10.1016/s1470-2045(21)00604-5

Article  CAS  PubMed  Google Scholar 

Sangro B, Chan S, Kelley R, Lau G, Kudo M, Sukeepaisarnjaroen W, De Toni E, Furuse J, Kang Y, Galle P, Rimassa L, Heurgué A, Tam V, Dao T, Thungappa S, Breder V, Ostapenko Y, Reig M, Makowsky M, Gupta C, Negro A, Abou-Alfa G (2023) SO-15 Four-year overall survival update from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. Ann Oncol 34:S168. https://doi.org/10.1016/j.annonc.2023.04.487

Article  Google Scholar 

Qin S, Chan SL, Gu S, Bai Y, Ren Z, Lin X, Chen Z, Jia W, Jin Y, Guo Y, Hu X, Meng Z, Liang J, Cheng Y, Xiong J, Ren H, Yang F, Li W, Chen Y, Zeng Y, Sultanbaev A, Pazgan-Simon M, Pisetska M, Melisi D, Ponomarenko D, Osypchuk Y, Sinielnikov I, Yang TS, Liang X, Chen C, Wang L, Cheng AL, Kaseb A, Vogel A (2023) Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study. Lancet. https://doi.org/10.1016/s0140-6736(23)00961-3

Cheng AL, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Lim HY, Kudo M, Breder V, Merle P, Kaseb AO, Li D, Verret W, Ma N, Nicholas A, Wang Y, Li L, Zhu AX, Finn RS (2022) Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol 76(4):862–873. https://doi.org/10.1016/j.jhep.2021.11.030

Article  CAS  PubMed  Google Scholar 

Finn RS, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle PR, Kaneko S, Kumada H, Wang A, Mody K, Dubrovsky L, Siegel AB, Llovet J (2022) LBA34 Primary results from the phase III LEAP-002 study: lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol 33:S1401. https://doi.org/10.1016/j.annonc.2022.08.031

Article  Google Scholar 

Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T (2022) Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 23(8):995–1008. https://doi.org/10.1016/s1470-2045(22)00326-6

Article  CAS  PubMed  Google Scholar 

Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, Chen Z, Liu B, Jia W, Wu J, Wang J, Shao G, Zhang B, Shan Y, Meng Z, Wu J, Gu S, Yang W, Liu C, Shi X, Gao Z, Yin T, Cui J, Huang M, Xing B, Mao Y, Teng G, Qin Y, Wang J, Xia F, Yin G, Yang Y, Chen M, Wang Y, Zhou H, Fan J (2021) Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol 22(7):977–990. https://doi.org/10.1016/s1470-2045(21)00252-7

Article  CAS  PubMed  Google Scholar 

Bang YJ, Golan T, Dahan L, Fu S, Moreno V, Park K, Geva R, De Braud F, Wainberg ZA, Reck M, Goff L, Laing N, Mi G, Oliveira JM, Wasserstrom H, Lin CC (2020) Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ). Eur J Cancer 137:272–284. https://doi.org/10.1016/j.ejca.2020.06.007

Article  CAS  PubMed